Palani Venkatesh, Mahesh Daggumati. Development and validation of a normal-phase HPTLC method for the simultaneous analysis of Lamivudine and Zidovudine in fixed-dose combination tablets[J]. Journal of Pharmaceutical Analysis, 2012, 02(2): 152-155. doi: 10.1016/j.jpha.2011.11.002
Citation:
Palani Venkatesh, Mahesh Daggumati. Development and validation of a normal-phase HPTLC method for the simultaneous analysis of Lamivudine and Zidovudine in fixed-dose combination tablets[J]. Journal of Pharmaceutical Analysis, 2012, 02(2): 152-155. doi: 10.1016/j.jpha.2011.11.002
Palani Venkatesh, Mahesh Daggumati. Development and validation of a normal-phase HPTLC method for the simultaneous analysis of Lamivudine and Zidovudine in fixed-dose combination tablets[J]. Journal of Pharmaceutical Analysis, 2012, 02(2): 152-155. doi: 10.1016/j.jpha.2011.11.002
Citation:
Palani Venkatesh, Mahesh Daggumati. Development and validation of a normal-phase HPTLC method for the simultaneous analysis of Lamivudine and Zidovudine in fixed-dose combination tablets[J]. Journal of Pharmaceutical Analysis, 2012, 02(2): 152-155. doi: 10.1016/j.jpha.2011.11.002
Simultaneous quantification of Lamivudine and Zidovudine in tablets by HPTLC method was developed and validated.The chromatograms were developed using a mobile phase of toluene:ethyl acetate:methanol (4∶4∶2,v/v/v) on pre-coated plate of silica gel GF aluminum TLC plate and quantified by densitometric absorbance mode at 276 nm.The Rf values were 0.41±0.03and 0.60±0.04 for Lamivudine and Zidovudine,respectively.The linearity of the method was found to be within the concentration range of 50-250 ng/spot for Lamivudine and for Zidovudine,it was 100-500 ng/spot.The lower limits of detection and quantification were 2.23 ng/spot and 7.90 ng/spot for Lamivudine and 2.90 ng/spot and 8.85 ng/spot for Zidovudine.The method was also validated for precision,specificity and recovery.This developed method was used to analyze fixed-dose tablets (Duovir,Cipla Ltd) samples of Lamivudine and Zidovudine.